Join the Mayzent group to help and get support from people like you.
Mayzent News
When Insurers Restrict MS Drug Coverage, Relapses Rise
TUESDAY, Aug. 5, 2025 — Multiple sclerosis (MS) patients might have a higher risk of relapse if their health insurance is stingy with prescriptions, a new study reports. Patients with insurance plans ...
Women Less Likely to Get Certain MS Meds Than Men
THURSDAY, July 31, 2025 — Women are less likely than men to receive multiple sclerosis (MS) meds that could help them manage the disease and delay disability, a new report finds. It could be that s...
Women With MS Less Likely Than Men to Receive Disease-Modifying Therapies
THURSDAY, July 31, 2025 – Women with multiple sclerosis (MS) are less likely to receive disease-modifying therapies (DMTs) than men, according to a study published online July 30 in Neurology....
FDA Approves Mayzent (siponimod) for Secondary Progressive Multiple Sclerosis
Basel, March 27, 2019 - Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent (siponimod) for the treatment of adults with relapsing forms of multiple...